Hernán Alarcón-Iniesta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hernán Alarcón-Iniesta has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- David García-Soriano
IMDEA Nanociencia, Campus Universitario de Cantoblanco, 28049 Madrid, Spain
1 shared publication - Gorka Salas
Instituto Madrileño de Estudios Avanzados en Nanociencia, Campus Universitario de Cantoblanco, 28049 Madrid, Spain
1 shared publication - Marco Cordani
Instituto de Investigaciones Sanitarias San Carlos (IdISSC), 28040, Madrid, Spain; Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, Complutense University of Madrid, 28040, Madrid, Spain
1 shared publication - Nuria Lafuente-Gómez
Fundacion IMDEA Nanociencia, Madrid, SPAIN
1 shared publication - Paula Milán-Rois
IMDEA Nanociencia, Madrid, Spain
1 shared publication - Yurena Luengo
Fundacion IMDEA Nanociencia, Madrid, SPAIN
1 shared publication
Latest Publications
- Open Access
Smart Modification on Magnetic Nanoparticles Dramatically Enhances Their Therapeutic Properties
Magnetic nanoparticles (MNP) are employed as nanocarriers and in magnetic hyperthermia (MH) for the treatment of cancers. Herein, a smart drug delivery system composed of MNP functionalized with the cytotoxic drug gemcitabine (MNP-GEM) has been thoroughly evaluated. The linker employed is based on a disulfide bond and allows the controlled release of GEM under a highly reducing environment, which is frequently present in the cytoplasm of tumor cells. The stability, MH, and the interaction with plasma proteins of the nanoparticles are evaluated, highlighting their great potential for biological applications. Their cytotoxicity is assessed in three pancreatic cancer cell lines with different sensitivity to GEM, including the generation of reactive oxygen species (ROS), the effects on the cell cycle, and the mechanisms of cell death involved. Remarkably, the proposed nanocarrier is better internalized than unmodified nanoparticles, and it is particularly effective in PANC-1 cells, resistant to GEM, but not in non-tumoral keratinocytes. Additionally, its combination with MH produces a synergistic cytotoxic effect in all cancer cell lines tested. In conclusion, MNP-GEM presents a promising potential for treating pancreatic cancer, due to multiple parameters, such as reduced binding to plasma proteins, increased internalization, and synergistic activity when combined with MH.
Open AccessSmart Modification on Magnetic Nanoparticles Dramatically Enhances Their Therapeutic Properties
Magnetic nanoparticles (MNP) are employed as nanocarriers and in magnetic hyperthermia (MH) for the treatment of cancers. Herein, a smart drug delivery system composed of MNP functionalized with the cytotoxic drug gemcitabine (MNP-GEM) has been thoroughly evaluated. The linker employed is based on a disulfide bond and allows the controlled release of GEM under a highly reducing environment, which is frequently present in the cytoplasm of tumor cells. The stability, MH, and the interaction with plasma proteins of the nanoparticles are evaluated, highlighting their great potential for biological applications. Their cytotoxicity is assessed in three pancreatic cancer cell lines with different sensitivity to GEM, including the generation of reactive oxygen species (ROS), the effects on the cell cycle, and the mechanisms of cell death involved. Remarkably, the proposed nanocarrier is better internalized than unmodified nanoparticles, and it is particularly effective in PANC-1 cells, resistant to GEM, but not in non-tumoral keratinocytes. Additionally, its combination with MH produces a synergistic cytotoxic effect in all cancer cell lines tested. In conclusion, MNP-GEM presents a promising potential for treating pancreatic cancer, due to multiple parameters, such as reduced binding to plasma proteins, increased internalization, and synergistic activity when combined with MH.